^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    vepsitamab (AMG 199)

    i
    Other names: AMG 199, AMG199, AMG-199
    Associations

    News

    Trials
    Company:
    Amgen, BeiGene
    Drug class:
    CD3 agonist, MUC17 inhibitor
    Related drugs:
    Associations

    News

    Trials
    over1year
    Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers (clinicaltrials.gov)
    P1, N=58, Terminated, Amgen | N=240 --> 58 | Active, not recruiting --> Terminated; Business decision
    Enrollment change • Trial termination
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability) • MUC17 (Mucin 17)
    |
    BRAF V600E • MSI-H/dMMR • BRAF V600 • BRAF wild-type
    |
    vepsitamab (AMG 199)
    almost2years
    Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers (clinicaltrials.gov)
    P1, N=240, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting | Trial completion date: Feb 2027 --> May 2023 | Trial primary completion date: Aug 2025 --> May 2023
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability)
    |
    BRAF V600E • MSI-H/dMMR • BRAF V600 • BRAF wild-type
    |
    vepsitamab (AMG 199)
    almost2years
    Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers (clinicaltrials.gov)
    P1, N=240, Recruiting, Amgen | Trial completion date: Oct 2025 --> Dec 2026 | Trial primary completion date: Mar 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability)
    |
    BRAF V600E • MSI-H/dMMR • BRAF V600 • BRAF wild-type
    |
    vepsitamab (AMG 199)
    2years
    Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers (clinicaltrials.gov)
    P1, N=240, Recruiting, Amgen | N=165 --> 240 | Trial completion date: Dec 2026 --> Oct 2025 | Trial primary completion date: Jun 2025 --> Mar 2024
    Enrollment change • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability)
    |
    BRAF V600E • MSI-H/dMMR • BRAF V600 • BRAF wild-type
    |
    vepsitamab (AMG 199)
    2years
    Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers (clinicaltrials.gov)
    P1, N=165, Recruiting, Amgen | Trial completion date: Apr 2025 --> Dec 2026 | Trial primary completion date: Sep 2023 --> Jun 2025
    Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability)
    |
    BRAF V600E • MSI-H/dMMR • BRAF V600 • BRAF wild-type
    |
    vepsitamab (AMG 199)
    almost3years
    Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers (clinicaltrials.gov)
    P1, N=165, Recruiting, Amgen | Trial primary completion date: Apr 2025 --> Aug 2023
    Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability)
    |
    BRAF V600E • MSI-H/dMMR • BRAF V600 • BRAF wild-type
    |
    vepsitamab (AMG 199)
    3years
    Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers (clinicaltrials.gov)
    P1, N=150, Recruiting, Amgen | Trial completion date: Nov 2025 --> Apr 2025 | Trial primary completion date: Nov 2025 --> Apr 2025
    Clinical • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability)
    |
    BRAF V600E • MSI-H/dMMR • BRAF V600 • BRAF wild-type
    |
    vepsitamab (AMG 199)
    3years
    Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers (clinicaltrials.gov)
    P1, N=150, Recruiting, Amgen | N=70 --> 150 | Trial completion date: Jun 2025 --> Nov 2025 | Trial primary completion date: Jun 2025 --> Nov 2025
    Clinical • Enrollment change • Trial completion date • Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability)
    |
    BRAF V600E • MSI-H/dMMR • BRAF V600
    |
    vepsitamab (AMG 199)
    over4years
    [VIRTUAL] A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE®) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer (ESMO-GI 2020)
    Key eligibility criteria include metastatic or locally advanced unresectable MUC17-positive (as determined by IHC using a central laboratory assay) gastric adenocarcinoma or gastroesophageal junction adenocarcinoma ineligible for curative surgery and relapsed or treatment-refractory following ≥2 lines including a platinum, a fluoropyrimidine, taxane or irinotecan, and an approved vascular endothelial growth factor receptor antibody or tyrosine kinase inhibitor. Legal entity responsible for the study Amgen, Inc. Funding Amgen, Inc.
    Clinical • P1 data
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    irinotecan • vepsitamab (AMG 199)
    over4years
    [VIRTUAL] Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer. (ASCO 2020)
    Key eligibility criteria include metastatic or locally advanced unresectable MUC17-positive (as determined by IHC using a central laboratory assay) gastric adenocarcinoma or gastroesophageal junction adenocarcinoma ineligible for curative surgery and relapsed or treatment-refractory following ≥2 lines including a platinum, a fluoropyrimidine, taxane or irinotecan, and an approved vascular endothelial growth factor receptor antibody or tyrosine kinase inhibitor. For more information, please contact Amgen Medical Information: medinfo@amgen.com. Research Funding: Amgen
    Clinical • P1 data
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    irinotecan • vepsitamab (AMG 199)